Use this page to scan recent stories from Labiotech, see the themes that keep appearing, and jump into complete story briefs.
Check out 10 of the top biotech companies in China, as the country has seen its biotech sector grow in the last decade. The post 15 biotech companies in China you should know about appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and
Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification. The post AstraZeneca’s pipeline strategy: building the next wave of growth appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this materia
From selecting the right system to overcoming integration challenges, discover how automated liquid handling can support flexible, reproducible laboratory workflows. The post Key considerations for adopting automated liquid handling platforms in pharmaceutical workflows appeared first on Labiotech.eu . © Labiotech UG a
PMOS, formerly called PCOS, is an understudied and underfunded field. While the drug pipeline is thin, we look at new treatments in studies. The post From PCOS to PMOS: what does the therapeutic field look right now? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication o
Our guest today is Thomas Ruggia, CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. The post Theialife’s race to bring a childhood myopia treatment to market appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized us
The life science sector is a key export industry in Sweden. A culture of collaboration has often been attributed to the progress. The post “An open and collaborative culture”: what makes Sweden attractive for life sciences appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplica
From data reveals and regulatory decisions to fundraising and biotech deals, let's look at key developments in oncology over the past month. The post Oncology biotech news: key moves to watch in September 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this
Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been approved. The post New Graft-versus-Host Disease treatments: What’s in the biotech pipeline in 2026? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplica
GLP-1 agonists go beyond treating metabolic disease. They have shown promise in treating MASH, addiction, sleep apnea, and neurodegeneration. The post What can GLP-1s do beside treat diabetes and obesity? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this mater
Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise. The post WCLC 2026: The lung cancer drug development readouts that caught our eye appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplicat
Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis. The post New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use
The German biotech ecosystem is well established despite the challenges it is facing. Discover ten key Germany-based biotech companies. The post Navigating German biotech: 10 companies to keep an eye on in 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this
Open the app view when you want faster scanning, saved stories, and source-focused reading in one place.